Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
Spread | 0.11 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022099% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000123% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
Prev. Close | 3.17 |
Open | 3.19 |
1-Year Change | -1.54% |
Day's Range | 3.14 - 3.19 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 23, 2024 | 3.17 | 0.03 | 0.96% | 3.14 | 3.24 | 3.14 |
Apr 22, 2024 | 3.16 | 0.09 | 2.93% | 3.07 | 3.22 | 3.07 |
Apr 19, 2024 | 3.08 | -0.03 | -0.96% | 3.11 | 3.14 | 3.08 |
Apr 18, 2024 | 3.12 | 0.04 | 1.30% | 3.08 | 3.17 | 3.08 |
Apr 17, 2024 | 3.11 | 0.01 | 0.32% | 3.10 | 3.18 | 3.10 |
Apr 16, 2024 | 3.11 | 0.01 | 0.32% | 3.10 | 3.20 | 3.08 |
Apr 15, 2024 | 3.16 | -0.07 | -2.17% | 3.23 | 3.29 | 3.16 |
Apr 12, 2024 | 3.24 | -0.01 | -0.31% | 3.25 | 3.44 | 3.23 |
Apr 11, 2024 | 3.30 | 0.10 | 3.12% | 3.20 | 3.34 | 3.20 |
Apr 10, 2024 | 3.22 | 0.06 | 1.90% | 3.16 | 3.26 | 3.14 |
Apr 9, 2024 | 3.21 | 0.09 | 2.88% | 3.12 | 3.26 | 3.12 |
Apr 8, 2024 | 3.16 | 0.09 | 2.93% | 3.07 | 3.21 | 3.05 |
Apr 5, 2024 | 3.15 | 0.03 | 0.96% | 3.12 | 3.17 | 2.98 |
Apr 4, 2024 | 3.23 | 0.07 | 2.22% | 3.16 | 3.24 | 3.16 |
Apr 3, 2024 | 3.23 | 0.10 | 3.19% | 3.13 | 3.24 | 3.13 |
Apr 2, 2024 | 3.14 | -0.10 | -3.09% | 3.24 | 3.30 | 3.14 |
Mar 28, 2024 | 3.28 | 0.04 | 1.23% | 3.24 | 3.32 | 3.23 |
Mar 27, 2024 | 3.24 | -0.03 | -0.92% | 3.27 | 3.32 | 3.24 |
Mar 26, 2024 | 3.26 | -0.01 | -0.31% | 3.27 | 3.31 | 3.22 |
Mar 25, 2024 | 3.32 | 0.03 | 0.91% | 3.29 | 3.33 | 3.24 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com